PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Icariin treated ovariectomized rats exhibited higher bone density and fewer TRAP-positive osteoclasts [PMID:38471268].
Icariin induced osteogenic differentiation of preosteoblastic cells and showed in vivo anabolic effects in a mouse calvarial defect model [PMID:19698057].
Icariin effectively inhibited osteoclast formation and bone resorption in RAW264.7 cells stimulated by titanium particles [PMID:24969548].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 22041065 (2011) — Flavonol glycosides from Epimedium pubescens. · Chemical & pharmaceutical bulletin
- 2.PMID: 36452098 (2022) — The discovery of a key prenyltransferase gene assisted by a chromosome-level Epimedium pubescens genome. · Frontiers in plant science
- 3.PMID: 41814816 (2026) — [Effects of different light qualities on field-grown Epimedium pubescens]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
- 4.PMID: 31905759 (2019) — A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages. · Molecules (Basel, Switzerland)
- 5.PMID: 36555695 (2022)